Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
Studies from H.T. Li et al in the area of gene therapy described
February 11th, 2009
According to recent research published in the journal Vaccine, "Human adenovirus type 3 (HAdV-3) cause respiratory infections globally. There is no safe and efficient HAdV-3 vaccine thus far." "In this report, a replication-defective human adenovirus type 3 was constructed by deletion of the whole El gene. A HEp-2 cell-based cell line designated HEp-2/E1 was generated and was shown to complement the function of El deleted mutant. A partial genome (9.5-100 mu) of HAdV-3 was cloned into pPolyll vector to be a backbone plasmid. A shuttle vector carrying eGFP gene was also constructed. The backbone and shuttle plasmids were co-transfected into the HEp-2/E1 cell line...
Source: Vaccine Weekly (2009-02-11)
|
